Randomized, double-blind, multicenter phase III trial to evaluate the efficacy and tolerability of brodalumab compared with the use of placebo (blind) and ustekinumab (open) in adolescent patients (12-17 years of age) with psoriasis in pl
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: LEO PHARMA A/S
- Phase: III
- Execution start: 03/02/2021
- End of execution: 30/12/2024
- IP: ANTONIO MARTINEZ LOPEZ